News & Therapies
Corporate Member Update: Merck
KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa pmph) November, 2025 Approval of KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa pmph) KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa pmph) Subcutaneous Injection 165 mg/2,000 units per mL...
Corporate Member Update: Amgen-New Technology Add On Payment/NTAP in SCLC
IMDELLTRA® (tarlatamab‑dlle) October, 2025 IMDELLTRA® (tarlatamab‑dlle) was granted New Technology Add On Payment (NTAP) by CMS, effective October 1st, 2025 for Medicare Beneficiaries in the inpatient setting. To read through full details on the IMDELLTRA‑ NTAP you...
AstraZeneca- Datroway J-Code
DATROWAY® October, 2025 Information available listed below as well as information on the new Datroway J‑Code: We now have a Pre‑approval Information Exchange (PIE) presentation available for SERENA‑6 our Phase III randomized trial to assess switching from AI + CDK4/6...
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) October, 2025 Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase 3 IMforte trial. Zepzelca and atezolizumab combination added to National Comprehensive...
Corporate Member Update: Merck
KEYTRUDA® (pembrolizumab) July, 2025 Merck would like to inform you that KEYTRUDA® (pembrolizumab) Injection 100 mg is approved for 42 indications across 18 types of cancer. • One indication that the FDA has now approved is KEYTRUDA for the treatment of adult patients...
Corporate Member Update- Jazz Pharmaceuticals
Ziihera® (zanidatamab-hrii) June, 2025 Jazz Pharmaceuticals announces U.S. FDA approval of Ziihera® (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2‑positive (IHC 3+) biliary tract cancer (BTC). Read the full...
Corporate Member Update- Menarini Stemline- ELEGANT clinical trial listing MED-05207 11/24
ELEGANT Clinical Trial May, 2025 ELEGANT clinical trial listing MED‑05207 11/24 A Phase 3 Study of elacestrant versus standard endocrine therapy in node‑positive ER+, HER2‑ early breast cancer with high risk of recurrence (ELEGANT) Despite advances in the adjuvant...
Corporate Member Update- Jazz Pharmaceuticals
Corporate Member Update- Amgen
LUMAKRAS® (sotorasib) May, 2025 We’re excited to share that LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) is approved in a new indication. Please see the product website and the full Prescribing Information for LUMAKRAS® and Vectibix® for more...
Corporate Member Update- Amgen
IMDELLTRA® (tarlatamab-dlle) April, 2025 New Coding Guidance for Amgen Product IMDELLTRA® (tarlatamab-dlle) received a permanent J‑Code J9026, Injection, tarlatamab-dlle, 1 mg. Effective for dates of service on or after January 1, 2025, the Centers for Medicare and...